drugset / Trial / NCT01601457

Activated Recombinant Human Factor VII in Pelvic-acetabular Fracture Reconstruction

NCT01601457

Phase 2 Completed 48 enrolled Novo Nordisk A/S
RandomizedParallel-groupDouble-blindTreatment

Summary

This trial is conducted in Europe. The aim of this trial is to evaluate the efficacy of activated recombinant human factor VIIgiven in conjunction with standard therapy in patients undergoing major orthopaedic surgery following traumatic pelvic or pelvic and acetabular fractures.

Timeline

Start
2002-09
Primary completion
2004-04
Completion
2004-04

Drugs

EvaluationDrugModalityDoseRoute
Subject eptacog alfa (activated) Protein / enzyme biologic 90 ug/kg Intravenous

Indications